LIPO (Lipella Pharmaceuticals) Ending Cash Position: $1.86 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Lipella Pharmaceuticals Ending Cash Position?

Lipella Pharmaceuticals LIPO -49.38% Ending Cash Position is $1.86 Mil as of Sep. 2025. The stock has 1 warning sign investors should review.

Lipella Pharmaceuticals's Ending Cash Position for the quarter that ended in Sep. 2025 was $1.86 Mil.

Lipella Pharmaceuticals's quarterly Ending Cash Position declined from Mar. 2025 ($4.23 Mil) to Jun. 2025 ($2.78 Mil) and declined from Jun. 2025 ($2.78 Mil) to Sep. 2025 ($1.86 Mil).

Lipella Pharmaceuticals's annual Ending Cash Position declined from Dec. 2022 ($5.12 Mil) to Dec. 2023 ($3.29 Mil) and declined from Dec. 2023 ($3.29 Mil) to Dec. 2024 ($2.19 Mil).

Lipella Pharmaceuticals Ending Cash Position Related Terms

Lipella Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Lipella Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipella Pharmaceuticals Ending Cash Position Chart

Lipella Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
0.61 1.41 5.12 3.29 2.19

Lipella Pharmaceuticals Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.35 2.19 4.23 2.78 1.86

Lipella Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Lipella Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=3.294+-1.109
=2.19

Lipella Pharmaceuticals's Ending Cash Position for the quarter that ended in Sep. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=2.782+-0.926
=1.86

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $1.86 Mil mean?
Lipella Pharmaceuticals (LIPO) has a Ending Cash Position of $1.86 Mil as of Sep. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Lipella Pharmaceuticals and its competitors.
Is Lipella Pharmaceuticals' Ending Cash Position too high?
Lipella Pharmaceuticals' current Ending Cash Position is $1.86 Mil.
How does Lipella Pharmaceuticals' Ending Cash Position compare to IOBTQ and WINT?
Lipella Pharmaceuticals' Ending Cash Position of $1.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Lipella Pharmaceuticals and its competitors. Lipella Pharmaceuticals's current Ending Cash Position is $1.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipella Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lipella Pharmaceuticals (LIPO) is currently considered Possible Value Trap. The stock's GF Value™ is $8.73, compared to a current price of $0.03 — trading 99.6% below its estimated fair value. The current Ending Cash Position is $1.86 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Lipella Pharmaceuticals (LIPO), the current Ending Cash Position is $1.86 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lipella Pharmaceuticals Business Description

Address 7800 Susquehanna Street, Suite 505, Pittsburgh, PA, USA, 15208
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.